Targeting AURKA by MiR-490-3p overcomes paclitaxel resistance in oral squamous cell carcinoma via NF-κB/STAT3 signaling
Archives of Biochemistry and Biophysics · 2026-08 · 782 · 110875
DOI: 10.1016/j.abb.2026.110875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026-08. Verfasst von Linfu Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan Provinc…. Hauptthemen laut MEDLINE: MicroRNAs, Aurora Kinase A, STAT3 Transcription Factor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Paclitaxel (PTX) resistance remains a major barrier to effective treatment of oral squamous cell carcinoma (OSCC). Although Aurora kinase A (AURKA) has been implicated in tumor progression, its functional role and regulatory mechanisms in PTX resistance are not fully understood. METHODS: PTX-resistant OSCC cell lines (CAL-27/PTX and SCC-9/PTX) were established from their PTX-naïve counterparts (CAL-27 and SCC-9, respectively) through stepwise exposure to increasing concentrations of PTX. AURKA was silenced using shRNA or regulated by miR-490-3p overexpression. Cell viability, apoptosis, migration, and invasion were assessed in vitro. NF-κB and STAT3 signaling activities were evaluated as downstream effectors. Direct targeting of AURKA by miR-490-3p was validated using dual-luciferase reporter assays. A xenograft model was used to assess the in vivo effects of AURKA knockdown on tumor growth and drug response. RESULTS: AURKA was significantly upregulated in PTX-resistant OSCC cells, accompanied by activation of NF-κB and STAT3 signaling. Functional inhibition of AURKA or restoration of miR-490-3p enhanced PTX sensitivity, promoted apoptosis, and suppressed migratory and invasive behaviors, together with attenuation of NF-κB/STAT3 activity. Mechanistically, miR-490-3p directly bound to the 3'-UTR of AURKA and negatively regulated its expression, whereas AURKA re-expression reversed these effects. In vivo, AURKA knockdown suppressed tumor growth, increased apoptotic activity, and inhibited NF-κB/STAT3 signaling in PTX-resistant xenografts. CONCLUSION: These findings identify a functional miR-490-3p/AURKA axis that regulates PTX resistance in OSCC through coordinated modulation of NF-κB and STAT3 signaling. Targeting this pathway may provide a promising strategy to overcome chemoresistance and inhibit OSCC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450003, China.
- Department of Oral and Maxillofacial Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450003, China. Electronic address: wygkyz@163.com.
Zitieren
APA
Han, L., Peng, L., Wang, X., Tong, C., Wu, Y., Li, W., Meng, X., & Wang, Y. (2026). Targeting AURKA by MiR-490-3p overcomes paclitaxel resistance in oral squamous cell carcinoma via NF-κB/STAT3 signaling. Archives of Biochemistry and Biophysics, 782, 110875. https://doi.org/10.1016/j.abb.2026.110875
Vancouver
Han L, Peng L, Wang X, Tong C, Wu Y, Li W, et al. Targeting AURKA by MiR-490-3p overcomes paclitaxel resistance in oral squamous cell carcinoma via NF-κB/STAT3 signaling. Archives of Biochemistry and Biophysics. 2026;782:110875. doi:10.1016/j.abb.2026.110875
BibTeX
@article{Han2026,
author = {Han, Linfu and Peng, Liwei and Wang, Xiqian and Tong, Chunshi and Wu, Yang and Li, Wen and Meng, Xin and Wang, Yonggong},
title = {Targeting AURKA by MiR-490-3p overcomes paclitaxel resistance in oral squamous cell carcinoma via NF-κB/STAT3 signaling},
journal = {Archives of Biochemistry and Biophysics},
year = {2026},
volume = {782},
pages = {110875},
doi = {10.1016/j.abb.2026.110875}
}
EUVIMED